Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

Sawnchey Feb. 2 at 9:37 PM

$FBIO $FBIOP For anyone more knowledgeable than me, just for some fun speculation, is there any legal reason why they couldn't buy out Avenue [maybe also one day Mustang] and take them private? Avenue in particular is essentially sat there burning cash and waiting for either Axsome to develop BAER-101 or some investor to hand them 100m to fund its P3. Since its market cap is curently a fraction of shareholder equity, surely it would be more efficient to just bring the whole thing back into the fold, cease ongoing operations and retain full control of the IP and assets? It seems the better option than holding onto a 10% stake in a zombie company. Hell if I had a million dollars (and FBIO didn’t have a perpetual voting control) I would try it myself. So I am just wondering if there is some sort of anti-fraud regulation that stops them from doing that sort of thing?

1 · Reply

makrodimutross Feb. 2 at 8:58 PM

$FBIOP $FBIO it will also benefit the company if they sell the PRV After March, because Cyprium PPS would only roll into FBIOP shares instead of being redeemed at 2x liquidation preference. This conversation sounds unusual to me. In essence, LR seems to be saying "the shareholders can wait to be paid." How about he does the same thing with Cyprium PPS then. Save the company plenty of cash to help them develop the AAV-ATP7 platform. Don't sell the PRV until after March... since it's "in the best interest of the company".

1 · Reply

Zellchair Feb. 2 at 4:43 PM

$FBIO $FBIOP $DERM Andrew Summers of Summers Value Partners keeping his focus and belief in EMROSI: https://www.readideabrunch.com/p/idea-brunch-with-andrew-summers-of

0 · Reply

Zellchair Feb. 2 at 4:42 PM

$FBIO $FBIOP Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites From today: https://www.prnewswire.com/news-releases/crystalys-therapeutics-expands-phase-3-ruby-study-with-first-patients-dosed-at-european-sites-302674720.html

0 · Reply

Zellchair Feb. 2 at 4:40 PM

$FBIO $FBIOP $CKPT Sun Pharma reported for the period Oct-Dec 2025 this weekend. Although they never give sales guidance, much of the UNLOXCYT content was worth listening to. For minute markers, listen between the minutes in earnings call: 10-11 23-25 29-30 35-36 41-42 https://sunpharma.com/wp-content/uploads/2026/01/FY26-Q3-Earnings-Call-Recording-10039711.mp3

1 · Reply

Sawnchey Feb. 2 at 9:01 AM

$FBIO $FBIOP I had this article appear in my inbox this morning: https://www.medscape.com/viewarticle/cmv-most-important-virus-no-one-talks-about-2026a10002ni?ecd=a2a Important to remember how much activity is going on at Fortress, Helocyte has already completed 4 studies of their Triplex vaccine for CMV, the FBIO corporate presentation also inclues Clinicaltrials codes for 8 additional trials, which if you click through most are recruiting still but the Adult HIV Phase 2 study completed enrollment further in the past than the primary endpoint window and so data should be ready at any moment. Fortress owns 83% of Helocyte, so this is another significant potential market opportunity which is reflected by roughly zero in the stock price.

0 · Reply

Zellchair Jan. 26 at 12:15 PM

$FBIO $FBIOP - Dotinurad is expected in studies to have a major impact on controlling Gout over a longer period of time. - Dotinurad is already used off label in Chronic Kidney Disease (CKD) in Japan. If it can be proven in a larger randomized study this is "huge and could affect a much larger population of people who are whose kidneys are basically failing. And if we can actually stop that decline in the kidney function, then that would be a real gamechanger as well." Try to remember here my previous posts about not stopping at Gout and specifically the evidence and theories that already exist for Dotinurad in CKD.

1 · Reply

makrodimutross Jan. 25 at 4:35 PM

$FBIOP Lindsay Rosenwald held 127,500 shares of FBIOP as of July 2024. If the PRV is sold by the end of March to provide Cyprium PPS their 2x liquidation preference, and the Fortress BOD votes to become current on their dividends in arrears to the preferred shareholders at some point in April... 21 months of dividends in arrears is $4.10 per share. Rosenwald will receive a net payment of $522,949. Likewise, if the company decides to fully redeem the shares, it would cost the company the $25 liquidation preference, plus the $4.10 in arrears, just shy of $100M in cash (less likely), Rosenwald would receive $3.7M. The company will likely lay out a plan similar to Care Cloud's in November (catch up / doubled payments until the arrears have been satisfied). I doubt they will redeem. Fortress is looking more like the retirement plan for Rosenwald and Weiss with each passing month.

1 · Reply

Zellchair Jan. 24 at 3:05 PM

$FBIO $FBIOP Perhaps it is appropriate to update the "fair value" in Q4? “Urica valued its equity holding in Crystalys using an option pricing model backsolve method (level 3 in the fair value hierarchy) to reassess the fair value of its investment in Crystalys after Crystalys announced a Series A financing and recognize additional shares received to maintain its 15% ownership percentage under the APA, resulting in an estimated fair value of $15.1 million which was recorded as other income in the condensed consolidated statement of operations during the three and nine months ended September 30, 2025” – Fortress Biotech Q3 2025, P. 21-22 https://www.fortressbiotech.com/investors/sec-filings/quarterly-reports

1 · Reply

Zellchair Jan. 24 at 3:02 PM

$FBIO $FBIOP Crystalys Therapeutics "With a current valuation of $800M, the company has demonstrated strong market traction and investor confidence." https://salestools.io/en/report/crystalys-therapeutics-205m-series-a https://pitchbook.com/profiles/company/897186-34#overview Before (importantly) SOBI bid for Arthrosi for up to $1.5B in December (expected to close in Q1), Crystalys was valued at $800M by PitchBook and Salestools after the latest Series A round. Now the floor should be set well above Arthrosis $1.5B (in my opinion). https://www.sobi.com/en/press-releases/sobi-acquire-arthrosi-therapeutics-strengthening-pipeline-potential-treatment-gout-2413046 CFO recruitment and CEO attendance whisper about IPO and/or buyout before IPO. https://www.prnewswire.com/news-releases/crystalys-therapeutics-expands-leadership-team-with-appointment-of-justin-thacker-as-chief-financial-officer-to-support-advancement-of-phase-3-trials-of-dotinurad-302665997.html https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-1-capital-allocation-and-dealmaking-U3B4EUN3GZGNXM6QI3ZGXVMNZY/ Dotinurad is already validated with 17 studies in Japan alone (excluding those in the US, China, Thailand & the Philippines).

1 · Reply

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A